Anton Drollmann
Overview
Explore the profile of Anton Drollmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
342
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huth F, Glaenzel U, Drollmann A, Weis W, Zack J, Bebrevska L
Clin Transl Sci
. 2024 Sep;
17(9):e70028.
PMID: 39288032
A drug-drug interaction (DDI) study was conducted to evaluate the effect of icenticaftor (QBW251) on the pharmacokinetics (PK) of a 5-probe cytochrome P450 (CYP) substrate cocktail, guided by in vitro...
2.
Iyer G, Darpo B, Xue H, Lecot J, Zack J, Bebrevska L, et al.
Clin Pharmacol Drug Dev
. 2024 Jan;
13(5):572-584.
PMID: 38284433
Icenticaftor (QBW251) is a potentiator of the cystic fibrosis transmembrane receptor. Based on its mechanism of action, icenticaftor is expected to provide benefits in patients with chronic obstructive pulmonary disease...
3.
Ji Y, Calonder C, Kirsila T, Burciu A, Tisu M, Joubert Y, et al.
Pharmaceutics
. 2023 Sep;
15(9).
PMID: 37765235
Ligelizumab is a highly potent, humanized IgG1, anti-IgE monoclonal antibody. To explore its optimal subcutaneous delivery, the pharmacokinetics (PK), pharmacodynamics (PD), and tolerability of ligelizumab from two Phase 1 studies...
4.
Staubach P, Alvaro-Lozano M, Sekerel B, Maurer M, Ben-Shoshan M, Porter M, et al.
Pediatr Allergy Immunol
. 2023 Jul;
34(7):e13982.
PMID: 37492920
Background: Chronic spontaneous urticaria (CSU), a long-lasting disease in children, impacts their quality of life. We report the results of a phase 2b dose-finding trial of ligelizumab (NCT03437278) and a...
5.
Schiller H, Huth F, Schuhler C, Drollmann A, Kaul M, Woessner R, et al.
Eur J Pharm Sci
. 2022 Mar;
172:106155.
PMID: 35247543
Purpose: Pharmacokinetic drug-drug interactions (DDIs) are investigated to ensure safety for patients receiving concomitant medications. Here, we present a strategy to characterise the DDI potential of remibrutinib, as an inhibitor...
6.
Singh D, Wild J, Saralaya D, Lawson R, Marshall H, Goldin J, et al.
Respir Res
. 2022 Feb;
23(1):26.
PMID: 35144620
Rationale: The long-acting β-agonist/long-acting muscarinic antagonist combination indacaterol/glycopyrronium (IND/GLY) elicits bronchodilation, improves symptoms, and reduces exacerbations in COPD. Magnetic resonance imaging (MRI) of the lung with hyperpolarized gas and gadolinium...
7.
Kulkarni S, Poller B, Drollmann A, Shah B, Gray C, Greco E, et al.
Pulm Pharmacol Ther
. 2021 Nov;
72:102097.
PMID: 34800680
No abstract available.
8.
Huth F, Schiller H, Jin Y, Poller B, Schuhler C, Weis W, et al.
Clin Transl Sci
. 2021 Aug;
15(1):118-129.
PMID: 34432364
Remibrutinib, a novel oral Bruton's Tyrosine Kinase inhibitor (BTKi) is highly selective for BTK, potentially mitigating the side effects of other BTKis. Enzyme phenotyping identified CYP3A4 to be the predominant...
9.
Vaidya S, Jauernig J, Ethell B, Abdallah N, Machineni S, Drollmann A, et al.
Pulm Pharmacol Ther
. 2020 Oct;
64:101964.
PMID: 33035700
Indacaterol (IND), is co-formulated with glycopyrronium (GLY), and mometasone furoate (MF) as a once-daily (o.d.) inhaled fixed-dose combination (IND/GLY/MF) delivered via the Breezhaler® device for maintenance treatment of asthma. We...
10.
Gauvreau G, Arm J, Boulet L, Leigh R, Cockcroft D, Davis B, et al.
J Allergy Clin Immunol
. 2016 May;
138(4):1051-1059.
PMID: 27185571
Background: Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE...